OTCPK:ACET.Q

Stock Analysis Report

Executive Summary

Aceto Corporation engages in the development, marketing, sale, and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals, and agricultural protection products.

Snowflake

Fundamentals

Adequate balance sheet with moderate growth potential.

Risks

  • Aceto has significant price volatility in the past 3 months.
  • Aceto's last earnings update was 209 days ago.
  • Aceto is not covered by any analysts.

Similar Companies

Share Price & News

How has Aceto's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.0%

OTCPK:ACET.Q

0.1%

US Healthcare

0.8%

US Market


1 Year Return

-95.3%

OTCPK:ACET.Q

-8.4%

US Healthcare

1.9%

US Market

ACET.Q underperformed the Healthcare industry which returned -7.7% over the past year.

ACET.Q underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

ACET.QIndustryMarket
7 Day8.0%0.1%0.8%
30 Day-21.3%-1.4%3.4%
90 Day-15.0%-0.7%2.1%
1 Year-95.3%-95.3%-7.0%-8.4%4.2%1.9%
3 Year-99.3%-99.3%30.6%25.3%46.7%37.2%
5 Year-99.3%-99.3%64.9%55.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Aceto's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aceto undervalued based on future cash flows and its price relative to the stock market?

0.083x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Aceto to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Aceto to establish if it is available at substantial discount.


Price Based on Earnings

Aceto is loss making, we can't compare its value to the US Healthcare industry average.

Aceto is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Aceto, we can't assess if its growth is good value.


Price Based on Value of Assets

Aceto is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Aceto expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

82.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Aceto is high growth as no revenue estimate data is available.

Aceto's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Aceto's revenue growth to the United States of America market average as no estimate data is available.

Aceto's earnings growth is expected to exceed the United States of America market average.

Aceto's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Aceto will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Aceto performed over the past 5 years?

-78.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Aceto does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Aceto's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Aceto's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Aceto has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Aceto has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Aceto improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Aceto's financial position?


Financial Position Analysis

Aceto is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Aceto's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Aceto's level of debt (630.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (11.3% vs 630.3% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Aceto has sufficient cash runway for more than 3 years based on current free cash flow.

Aceto has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -22.1% each year.


Next Steps

Dividend

What is Aceto's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Aceto's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Aceto's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Aceto has not reported any payouts.

Unable to verify if Aceto's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Aceto has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Aceto's salary, the management and board of directors tenure and is there insider trading?

7.2yrs

Average management tenure


CEO

Aceto has no CEO, or we have no data on them.


Management Age and Tenure

7.2yrs

Average Tenure

57yo

Average Age

The average tenure for the Aceto management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.1yrs

Average Tenure

64.5yo

Average Age

The tenure for the Aceto board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$10,11427 Feb 19
Frank DeBenedittis
EntityIndividual
Role
Senior Key Executive
SVP of Corporate Business Development & International SVP of Active Pharmaceutical Ingredients
Shares47,130
Max PriceUS$0.21

Ownership Breakdown


Management Team

  • Frank DeBenedittis (65yo)

    SVP of Corporate Business Development & International SVP of Active Pharmaceutical Ingredients

    • Tenure: 18.7yrs
    • Compensation: US$859.74k
  • Ray Bartone (57yo)

    Senior Vice President of Nutritionals

    • Tenure: 7.2yrs
  • Gary Mo

    Head of Asian Sourcing Operations

    • Tenure: 9.4yrs
  • Alexander Elo

    Managing Director of Aceto Health Ingredients Gmbh

    • Tenure: 0yrs
  • Charles Alaimo (53yo)

    Senior Vice President of Human Resources

    • Tenure: 7.2yrs
  • Steven Rogers (58yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$901.98k
  • Terry Kippley (55yo)

    Senior Vice President of Agricultural Protection Products

    • Tenure: 7.2yrs
  • Keith Wilkinson

    Senior Vice President of Performance Chemicals

    • Tenure: 2.4yrs

Board Members

  • Alan Levin (57yo)

    Non-Executive Chairman of the Board

    • Tenure: 1.2yrs
    • Compensation: US$216.50k
  • Al Eilender (76yo)

    Chairman Emeritus

    • Tenure: 1.2yrs
    • Compensation: US$1.42m
  • Natasha Giordano (59yo)

    Director

    • Tenure: 8.7yrs
    • Compensation: US$166.50k
  • William Britton (74yo)

    Director

    • Tenure: 13.7yrs
    • Compensation: US$211.00k
  • Dan Yarosh (65yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$206.75k
  • Bill Kennally (64yo)

    Director

    • Tenure: 3yrs
    • Compensation: US$3.56m

Company Information

Aceto Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aceto Corporation
  • Ticker: ACET.Q
  • Exchange: OTCPK
  • Founded: 1947
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$4.163m
  • Shares outstanding: 30.84m
  • Website: https://www.aceto.com

Number of Employees


Location

  • Aceto Corporation
  • 4 Tri Harbor Court
  • Port Washington
  • New York
  • 11050
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACET.QOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 1969
AZJDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1969

Biography

Aceto Corporation engages in the development, marketing, sale, and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:30
End of Day Share Price2019/09/17 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.